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OBJECTIVE — Recent studies suggested an impact of prandial insulin delivery on postpran-
dial regulation of tissue blood ﬂow. This study compared the effect of VIAject with human
regular insulin and insulin lispro on postprandial oxidative stress and endothelial function in
patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Fourteen patients (seven men; aged 61.5 
1.8 years; duration of diabetes 6.6  4.6 years; A1C 7.2  0.5% [mean  SEM]) received a
prandial injection of VIAject, human regular insulin, and insulin lispro. At baseline and after a
standardized liquid meal test (Ensure Plus), the postprandial increases in asymmetric dimethy-
larginine(ADMA)andnitrotyrosinelevelswereinvestigated.Inaddition,thepostprandialeffects
on microvascular blood ﬂow, skin oxygenation, and vascular elasticity were measured.
RESULTS — Treatment with VIAject resulted in a signiﬁcant reduction in the peak postpran-
dial generation of ADMA compared with human insulin and insulin lispro (VIAject 27.3 
22.6,humaninsulin97.724.4,andinsulinlispro66.933.9nmol/l;P0.05,respectively).
The postprandial increases in nitrotyrosine levels were signiﬁcantly less after VIAject than after
humanregularinsulin(VIAject0.220.17vs.humaninsulin0.250.15g/ml;P0.05),
whereasnitrotyrosineafterinsulinlisprowasinbetween(insulinlispro0.090.07g/ml;NS).
In parallel, earlier and more pronounced increases in microvascular blood ﬂow and skin oxy-
genation were obtained after VIAject compared with those after human insulin or insulin lispro
(P  0.05, respectively). All insulin formulations resulted in comparable improvements in
central arterial elasticity.
CONCLUSIONS — Treatment with VIAject reduced postprandial oxidative stress and im-
proved endothelial function compared with human regular insulin or insulin lispro.
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T
ype 2 diabetes is closely related to
atherosclerosis and the develop-
ment of cardiovascular complica-
tions such as myocardial infarction or
stroke. Recent studies on cardiovascular
endpointsinpatientswithtype2diabetes
call into question the value of A1C-
focusedtreatmentsinreducingmacrovas-
cular complications of diabetes (1–3).
Other markers such as glucose excur-
sions, hypoglycemia, or postprandial
generationofoxidativestressmayaddim-
portant information for the judgment of
cardiovascularriskinpatientswithtype2
diabetes (1,2). Postprandial microvascu-
lar blood ﬂow is under dynamic regula-
tion and is diversely affected by changes
in postprandial glucose and insulin levels
(4). Increasing postprandial insulin levels
stimulatemicrovascularbloodﬂowbyin-
ducing the endothelial release of nitric
oxide via the activation of the phosphati-
dylinositol 3-kinase system (5,6). In con-
trast,increasingbloodglucoselevelswere
shown to oppose the insulin effects on
endothelial cells and to impair postpran-
dial microvascular blood ﬂow (7). A re-
duced ﬁrst-phase insulin release with an
augmented increase in postprandial glu-
cose levels followed by an impairment in
endothelial function and postprandial
microvascular blood ﬂow is an early fea-
ture of type 2 diabetes (4,8). These ﬁnd-
ings suggest that a physiological timing of
prandial insulin release fulﬁlls an impor-
tantrolenotonlyincontrollingpostpran-
dial blood glucose levels but also in
maintaining normal tissue perfusion and
nutrition. In addition, recent studies have
shown that in insulin-treated patients
with type 1 and type 2 diabetes, the phar-
macokinetic proﬁle of insulin formula-
tions affects postprandial microvascular
blood ﬂow and that treatment with fast-
acting insulin analogs reduces post-
prandial oxidative stress and restores
endothelial function more effectively
than treatment with human regular in-
sulin (9–11).
VIAject is a new, ultra–fast-acting in-
sulin formulation shown to have more
rapid insulin absorption than that for hu-
man regular insulin and insulin lispro.
The aim of this study was to compare the
effect of preprandial subcutaneous ad-
ministration of insulin VIAject with pre-
prandial application of human regular
insulin and insulin lispro on several
markers of endothelial and microvascular
function after a standardized liquid meal
test in patients with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Fifteen patients with
type 2 diabetes receiving stable sulfonyl-
ureaand/ormetformintreatmentwerere-
cruited for study participation. Patients
were excluded if they had been treated
with insulin, peroxisome proliferator–
activated receptor- agonists, glinides, or
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weeks before screening. All other con-
comitant treatment was kept stable dur-
ing study participation. Additional
exclusion criteria were evidence of major
micro- or macrovascular complications
and impaired cardiovascular, respiratory,
hepatic, or renal function. One patient
dropped out of the study because of per-
sonaltimerestrictionsanddidnotreceive
the last insulin treatment. Fourteen pa-
tients who received all protocol-speciﬁed
insulin treatments were included in the
analyses.
Study procedure
This open-label study consisted of a
three-arm crossover with each treatment
administeredinrandomsequenceonsep-
arate study days. Regular human insulin
was given at a dose of 0.10 unit/kg. To
minimize risk of hypoglycemia, 90% of
this dose was used for the insulin lispro
administration, and 75% of the regular
human insulin dose was used for VIAject
administrations. Because this lower VIA-
ject dose did not result in postprandial
glucose control comparable to that with
regular human insulin and lispro treat-
ments, all subjects underwent a subse-
quent VIAject administration at 90% of
theregularhumandoseaftertherandom-
ized sequence. This dose administration
resulted in matched postprandial glucose
control and forms the basis for the be-
tween-treatment comparisons presented.
For study drug administrations, pa-
tients arrived at the study site on the
morningafteranovernightfastforatleast
8 h. An intravenous cannula for blood
samplingwasinsertedintoalargeantecu-
bital or forearm vein. Subjects remained
supine for the duration of the investiga-
tions on each investigational day. Human
regular insulin was injected 15 min in ad-
vance and insulin VIAject or lispro was
injected immediately before the intake of
a standardized liquid meal (Ensure Plus,
containing 56% carbohydrates, 29% fat,
and 15% protein). No other food or
drinks, with the exception of small
amounts of mineral water, were allowed
during the investigational period of 4 h.
At baseline (before liquid meal intake)
and at 10, 20, 30, 60, 120, 180, and 240
minaftertheliquidmeal,bloodwastaken
for the measurement of asymmetric dim-
ethylarginine (ADMA), blood glucose,
and insulin. Because of time limitations,
the microvascular blood ﬂow (laser
Doppler ﬂux [LDF]), tissue oxygenation
(SO2), the arterial elasticity index (aug-
mentation index [Aix]), and nitrotyrosine
measurementswereonlytakenatbaseline
and at 30, 60, 120, 180, and 240 min
thereafter.
Skin blood ﬂow and oxygen
saturation measurement
The technique of simultaneous micro-
lightguide spectrophotometry and laser
Doppler ﬂuxmetry was used to measure
microvascularskinbloodﬂowandHbox-
ygenation at the lower forearm (O2C;
LEAMedizintechnik,Giessen,Germany).
A skin probe (LF 2; LEA Medizintechnik)
wasplacedonthethenarsurfaceoftheleft
hand in between the phalanx of the
thumb and the metatarsal of the foreﬁn-
ger, directly adjacent to the abductor pol-
licis muscle. LDF and tissue oxygen
tension measurements (SO2) were per-
formed at the time points given above. As
shown in a previous study, this technique
allows LDF measurements with a coefﬁ-
cient of variation of 10% and oxygen
saturation measurements with a coefﬁ-
cient of variation of 20% (12).
Measurement of central arterial
elasticity
Centralarterialelasticitywasmeasuredby
the technique of applanation tonometry
using a highly sensitive transducer
(Sphygmo Cor; AtCor Medical, West
Ryde, Australia). The central arterial
waveformwasderivedfrom20sequential
waveform records obtained from the pe-
ripheral radial artery using a validated
transfer function (13). Only high-quality
recordings, deﬁned as an in-device qual-
ity index with 80% reproducibility,
were included in the analysis. The aug-
mentation pressure was obtained from
thedifferencebetweenthesecondandthe
ﬁrst systolic shoulder of the central pres-
sure wave curve, and the Aix was calcu-
lated as the percentage of augmentation
pressure from total pulse pressure.
Laboratory measurements
All laboratory measurements were ana-
lyzed at the Institute for Clinical Re-
search and Development (ikfe, Mainz,
Germany). Blood samples were centri-
fuged and kept at 20°C until ﬁnal
analysis. Plasma glucose concentrations
were determined by the glucose dehy-
drogenase method (Super GL; RLT,
Mo ¨hnesee-Delecke, Germany). ADMA
was determined by an enzyme-linked
immunosorbent assay according to the
manufacturer’s guidelines (ADMA
ELISA; Immundiagnostik, Bensheim,
Germany). Insulin and nitrotyrosine
were measured by chemoluminescence
assays (insulin: Invitron, Monmouth,
U.K.;nitrotyrosine:UpstateBiotechnol-
ogy, Charlottesville, VA). Insulin lispro
was measured using a radioimmunoassay
(Linco Laboratories, St. Charles, MO). A1C
was measured by high-performance liquid
chromatography (Menarini Diagnostics,
Neuss, Germany).
Statistical analysis
ADMA was chosen as the primary end
point because a previous study had dem-
onstrated a signiﬁcant impact of fast-
acting analogs on the generation of
postprandial ADMA levels in patients
withtype2diabetes(10).Asamplesizeof
14patientswascalculatedtoprovide80%
power, assuming a comparable effect on
the postprandial excursion of plasma
ADMAlevelsandconsideringatwo-sided
test with a signiﬁcance level of 5%.
This study was designed as a pilot
study, without conﬁrmatory sample size
consideration. All measurements are pre-
sented as means  SEM. Statistical com-
parison between fasting and postprandial
values and between groups was per-
formed using the Student t test (paired
and unpaired as appropriate); P  0.05
(two-tailed) was considered statistically
signiﬁcant. Spearman correlation coefﬁ-
cients were calculated for each pair of
variables. Peak postprandial ADMA and
nitrotyrosine response was deﬁned as the
maximum increase from baseline within
120 min after the uptake of the liquid
meal.
RESULTS— Seven female and seven
male patients with type 2 diabetes were
included in the per-protocol analysis of
thestudy.MeanSDagewas61.56.7
years, duration of diabetes was 6. 6  4.6
years, A1C was 7.2  0.5%, and BMI was
31.0  3.4 kg/m
2.
As shown in Table 1, absolute plasma
glucose levels and the time course of
plasma glucose levels were comparable
during all three kinds of insulin treat-
ment. Because the active ingredient in
VIAjectisrecombinanthumanregularin-
sulin, human regular insulin and VIAject
insulin were measured using the same in-
sulin assay, whereas insulin lispro was
measured with a lispro-speciﬁc assay,
minimizing detection of endogenous in-
sulin.ComparingVIAjectwithhumanin-
sulin, plasma insulin levels showed a
steeper increase within the ﬁrst 60 min
and a faster decrease from 60 min on-
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used, quantitative comparisons among
the insulin levels after insulin lispro and
the human insulin formulations are not
useful.
Postprandial plasma ADMA levels in-
creased during treatment with human in-
sulin and during treatment with insulin
lispro (Table 1). The maximal increase in
plasma ADMA levels was found 20 min
after the meal during human insulin and
insulinlisprotreatment,whereasnopost-
prandial increase in ADMA levels was ob-
servedduringVIAjecttreatment.Figure1
shows the peak postprandial ADMA re-
sponse (20 min postprandial) according
to the three treatment conditions. The
maximal change in postprandial ADMA
levels was signiﬁcantly lower when
VIAject was compared with human regu-
lar insulin or insulin lispro. As shown in
Table 2, postprandial nitrotyrosine levels
increased during treatment with human
regular insulin and to a lesser extent with
insulin lispro. The maximal increase in
plasma nitrotyrosine levels was found 30
min after the meal during human insulin
and during insulin lispro treatment,
whereas no postprandial increase in ni-
trotyrosine levels was observed during
VIAject treatment. Figure 2 shows the
peak postprandial nitrotyrosine response
(30 min postprandial) according to the
three treatment conditions. The maximal
increaseinpostprandialnitrotyrosinelev-
els was signiﬁcantly lower when VIAject
was compared with human insulin but
notwithinsulinlispro.Incontrast,micro-
vascular blood ﬂow consistently in-
creased during the ﬁrst 60 min after the
injection of VIAject (Table 2). A signiﬁ-
cantly larger increase in microvascular
blood ﬂow was found after VIAject com-
pared with that after human regular insu-
linorinsulinlisproduringtheﬁrst60min
after injection. In parallel with microvas-
cular skin blood ﬂow, skin oxygenation
temporarily declined after the injection of
human regular insulin and insulin lispro,
whereas a consistent increase in skin ox-
ygenationcouldbeobservedafterVIAject
during 60 min after the test meal.
Changesinskinmicrovascularbloodﬂow
were correlated with changes in skin ox-
ygenation (r  0.58, P  0.0001).
All insulin formulations improved ar-
terial elasticity as given by a decrease in
the Aix with no differences observed
among the insulin formulations.
CONCLUSIONS — Type 2 diabetes
is associated with an increase in micro-
and macrovascular complications. There
is increasing evidence that postprandial
metabolism including the generation of
postprandial oxidative stress might pre-
dict vascular risk to a greater extent than
A1Corfastingglucosevalues(14,15).Be-
sides its role in the regulation of glucose
metabolism, insulin has been shown to
mediate important vascular effects by
stimulating the endothelial secretion of
nitricoxide(5,16).Recentstudiessuggest
that the pharmacokinetic proﬁle of sub-
cutaneous insulin absorption might have
an impact on the generation of postpran-
dial oxidative stress and the development
of endothelial dysfunction (9–11,17). In-
sulin may directly affect the generation or
degradation of ADMA, and insulin resis-
tance is associated with increased ADMA
levels (18,19). ADMA has been identiﬁed
as the major endogenous inhibitor of the
physiologicalnitricoxidesynthasesystem
(20). Elevated ADMA levels cause endo-
thelialnitricoxidesynthaseuncoupling,a
mechanism that leads to decreased nitric
oxide availability. A study by Fard et al.
Figure 1—Peak postprandial change in plasma ADMA levels. *P  0.05 vs. VIAject. HI, human
insulin; LI, insulin lispro; VJ, VIAject.
Table1—Changefrombaselineinglucose,insulin,andADMAat10,20,30,60,120,180,and
240 min postprandial
Treatment Time (min) Glucose (mg/dl) Insulin (U/ml) ADMA (nmol/l)
HI 10 5.4  2.5 13.7  3.6 3.3  21.9
LI 10 6.4  4.7 6.8  4.2 9.1  18.8
VJ 10 21.1  4.9*† 20.5  3.2 9.3  30.3
HI 20 19.7  5.1 26.1  5.2 97.7  24.4
LI 20 27.2  9.4 17.1  6.0 66.9  33.9
VJ 20 35.6  4.7 42.7  5.9* 27.3  22.6*†
HI 30 33.6  6.4 34.1  5.7 27.1  29.3
LI 30 39.9  10.5 21.8  6.3 2.0  35.8
VJ 30 42.4  7.3 45.1  4.6 35.9  37.6
HI 60 60.8  12.8 37.9  6.1 14.1  28.4
LI 60 49.9  7.4 24.8  6.2 8.6  38.3
VJ 60 52.4  10.2 47.2  6.9 43.4  37.1
HI 120 34.6  9.3 32.6  2.8 3.1  26.1
LI 120 31.2  11.6 16.8  3.9 27.2  34.4
VJ 120 19.5  8.8 31.3  3.7 28.8  33.9
HI 180 7.3  9.1 17.8  2.4 18.2  33.9
LI 180 19.5  15.3 1.4  1.9 46.2  27.8
VJ 180 7.1  9.7 16.0  2.7 9.9  24.6
HI 240 37.9  7.0 9.2  1.3 48.2  40.7
LI 240 46.1  10.8 4.5  0.9 11.3  33.7
VJ 240 3.9  6.8 4.8  1.2* 94.3  25.2*
Data are means SEM. *P  0.05 vs. human regular insulin. †P  0.05 vs. insulin lispro. (Because they are
measuredwithdifferentassays,lisprovs.humaninsulincomparisonsarenotpresented).HI,humaninsulin;
LI, insulin lispro; VJ, VIAject.
Insulin and postprandial vascular function
118 DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 care.diabetesjournals.org(21) showed that plasma levels of ADMA
were accentuated after high-fat meals.
This was accompanied by a decline in
endothelial function, as indicated by a
reduction in the ﬂow-mediated vasodila-
tion of the brachial artery. In a recent
study, we were able to demonstrate that
the time course of subcutaneous insulin
absorption has an impact on the genera-
tion of postprandial ADMA levels, sup-
porting the hypothesis that postprandial
metabolism signiﬁcantly inﬂuences
atherogenic potency in patients with type
2 diabetes (10).
VIAject is a newly developed human
insulin formulation that has been shown
to provide more rapid subcutaneous ab-
sorption than human regular insulin and
fast-acting insulin analogs in lean nondi-
abetic subjects (22). In agreement with
this observation, our investigation con-
ﬁrmed more rapid absorption of subcuta-
neously administered VIAject compared
with that of human regular insulin or in-
sulin lispro in patients with type 2 diabe-
tes. Non–insulin-treated patients with
type 2 diabetes received a single dose of
each insulin formulation, which was
calculated according to the patient’s
body weight and not adjusted for post-
prandial glucose excursions. Even
thoughpostprandialglucoseexcursions
were well matched between the regular
human insulin and 90% lispro and
VIAject treatments, the treatments
could be differentiated in that VIAject
treatments were associated with a re-
duction in postprandial ADMA levels
and a diminished generation of oxida-
tive stress.
In addition to the laboratory markers
for postprandial endothelial function and
oxidative stress, our study revealed that
VIAject increases microvascular blood
ﬂow in the skin comparable to the post-
prandial increase in microvascular blood
ﬂow in nondiabetic control subjects (4).
In accordance with the increase in micro-
vascular skin blood ﬂow, postprandial
skin oxygenation increased after the in-
jection of VIAject.
Systemic arterial stiffness or reduced
compliance is an independent predictor
of coronary artery disease and cardio-
vascular mortality. In a recent study, an
increase in arterial compliance was ob-
served after the intake of a carbohydrate-
rich meal, which was predicted by the
magnitude of glucose and insulin re-
sponse (23). Euglycemic clamp studies
revealedthatinsulinratherthanglucoseis
the main determinant of arterial stiffness
in the postprandial state (24), and the ki-
netics of the postprandial insulin release
might have an impact on the modulation
ofarterialstiffness.Incontrasttothemore
distinct effects on microvascular blood
ﬂow in skin, all insulin formulations in
our study improved vascular elasticity
comparably.Althoughinsulinhasproven
to exert its vasodilatory effect on periph-
eral resistance vessels by activation of
phosphatidylinositol 3-kinase and subse-
quent nitric oxide release from the endo-
thelialcell,insulineffectsonlargearteries
and the mechanism by which insulin
modulates arterial elasticity is less clear
(23,25). The distinct vascular effects of
insulin observed in microvascular blood
ﬂow and in central arterial compartments
observedinourstudyimplythatthereare
differential effects on microvascular cir-
culation and central arteries.
In summary, our study conﬁrms im-
portant implications of prandial insulin
kinetics for the regulation of endothelial
integrity and microvascular function in
patients with type 2 diabetes. The ultra-
rapid absorption of VIAject insulin was
associated with a reduction in postpran-
dial oxidative stress and improvements in
microvascular function after a liquid test
meal more so than that after human reg-
ularinsulinorafast-actinginsulinanalog.
This study has important limitations.
Itwasanexploratorystudytoevaluatethe
vascular effects of the new ultra-rapid in-
sulin VIAject and needs to be conﬁrmed
by larger conﬁrmatory studies. It is not
known whether single-dose administra-
Figure 2—Peak postprandial change in plasma nitrotyrosine levels *P  0.05 vs. VIAject. HI,
human insulin; LI, insulin lispro; VJ, VIAject.
Table 2 —Change from baseline in nitrotyrosine, skin blood ﬂow (LDF), skin oxygen tension
(SO2), and pulse wave index (Aix) at 30, 60, 120, 180, and 240 min postprandial
Treatment Time (min)
Nitrotyrosine
(g/ml) LDF (AU) SO2 (%) Aix (%)
HI 30 0.25  0.15 2.2  2.5 2.1  1.1 3.9  1.4
LI 30 0.09  0.07 5.0  4.5 2.4  1.6 1.1  1.6
VJ 30 0.26  0.17* 4.1  2.4*† 2.5  2.3*† 3.0  2.2
HI 60 0.22  0.17 1.2  3.1 1.9  1.6 5.0  1.1
LI 60 0.05  0.16 1.9  7.6 2.5  1.9 3.5  1.4
VJ 60 0.03  0.20 7.1  5.7 2.7  2.4*† 3.5  1.8
HI 120 0.22  0.23 5.4  2.2 0.4  1.2 2.6  1.8
LI 120 0.16  0.18 0.5  3.5 1.4  1.7 0.3  1.7
VJ 120 0.00  0.22 3.1  5.0 0.6  2.4 2.8  1.5
HI 180 0.06  0.24 4.8  2.9 0.8  1.5 0.9  1.3
LI 180 0.06  0.22 1.2  7.3 0.6  2.1 2.6  1.7
VJ 180 0.16  0.17 4.5  7.6 0.8  2.2 1.6  2.4
HI 240 0.16  0.24 1.1  3.3 1.2  1.2 0.4  1.2
LI 240 0.07  0.23 1.4  6.7 1.2  1.4 1.1  1.2
VJ 240 0.26  0.18 9.1  9.4 0.8  1.8 0.8  2.2
Data are means  SEM. *P  0.05 vs. human regular insulin. †P  0.05 vs. insulin lispro. AU, arbitrary
units; HI, human insulin; LI, insulin lispro; VJ, VIAject.
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with chronic dosing. Further studies with
larger patient populations and longer ob-
servationalperiodsarenecessarytoascer-
tain the clinical impact of the results
obtained in this short-term mechanistic
study.Thestudydidnotincludeahealthy
control group. Therefore, no conclusion
can be made as to what degree the insulin
treatments were able to normalize post-
prandial oxidative stress and endothelial
function in type 2 diabetic patients.
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